Keros Therapeutics, Inc.
About Keros Therapeutics, Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $244.1M
- Net income
- $87.0M
- Total assets
- $338.0M
- Market cap
- $203.9M
- Operating margin
- 27.7%
- Net margin
- 35.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $243.9M
- Operating expenses
- $176.5M
- Operating income
- $67.6M
- Income tax
- $4.9M
- Net income
- $87.0M
- EPS (basic)
- $2.34
- EPS (diluted)
- $2.30
Balance sheet
- Total assets
- $338.0M
- Current assets
- $315.4M
- Total liabilities
- $34.9M
- Current liabilities
- $20.4M
- Shareholders’ equity
- $303.1M
Cash flow
- Operating cash flow
- $107.5M
- Investing cash flow
- -$1.6M
- Financing cash flow
- -$378.5M
- Net cash flow
- -$272.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $203.9M
- P/E ratio
- 4.3
- EPS (diluted)
- $2.3
- Shares outstanding
- 20.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 8, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $87.0M in FY2025.
- Revenue grew 1113% from FY2021 to FY2025.
- Trading 54% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Keros Therapeutics, Inc..
Write a review
News about Keros Therapeutics, Inc.
News & sentiment via Polygon.io
